Search

Your search keyword '"Mahfoud, Felix"' showing total 2,152 results
Start Over Author "Mahfoud, Felix"
2,152 results on '"Mahfoud, Felix"'

203. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: ESC/ESH Task Force for the Management of Arterial Hypertension

Author

Williams, Bryan, Mancia, Giuseppe, Spiering, Wilko, Agabiti Rosei, Enrico, Azizi, Michel, Burnier, Michel, Clement, Denis, Coca, Antonio, De Simone, Giovanni, Dominiczak, Anna, Kahan, Thomas, Mahfoud, Felix, Redon, Josep, Ruilope, Luis, Zanchetti, Alberto, Kerins, Mary, Kjeldsen, Sverre, Kreutz, Reinhold, Laurent, Stephane, Lip, Gregory Y.H., McManus, Richard, Narkiewicz, Krzysztof, Ruschitzka, Frank, Schmieder, Roland, Shlyakhto, Evgeny, Tsioufis, Konstantinos, Aboyans, Victor, and Desormais, Ileana

Published
2018
Full Text
View/download PDF

206. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

Author

Böhm, Michael, primary, Anker, Stefan, additional, Mahfoud, Felix, additional, Lauder, Lucas, additional, Filippatos, Gerasimos, additional, Ferreira, João Pedro, additional, Pocock, Stuart J, additional, Brueckmann, Martina, additional, Saloustros, Ilias, additional, Schüler, Elke, additional, Wanner, Christoph, additional, Zannad, Faiez, additional, Packer, Milton, additional, and Butler, Javed, additional

Published
2022
Full Text
View/download PDF

207. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Author

Schlaich, Markus P, primary, Bellet, Marc, additional, Weber, Michael A, additional, Danaietash, Parisa, additional, Bakris, George L, additional, Flack, John M, additional, Dreier, Roland F, additional, Sassi-Sayadi, Mouna, additional, Haskell, Lloyd P, additional, Narkiewicz, Krzysztof, additional, Wang, Ji-Guang, additional, Reid, Christopher, additional, Schlaich, Markus, additional, Katz, Ivor, additional, Ajani, Andrew, additional, Biswas, Sinjini, additional, Esler, Murray, additional, Elder, Grahame, additional, Roger, Simon, additional, Colquhoun, David, additional, Mooney, John, additional, De Backer, Tine, additional, Persu, Alexandre, additional, Chaumont, Martin, additional, Krzesinski, Jean-Marie, additional, Vanassche, Thomas, additional, Girard, Ginette, additional, Pliamm, Lew, additional, Schiffrin, Ernesto, additional, Merali, Fatima, additional, Dresser, George, additional, Vallee, Michel, additional, Jolly, Shivinder, additional, Chow, Stephen, additional, Wang, Jiguang, additional, Mu, Jianjun, additional, Yu, Jing, additional, Yuan, Hong, additional, Feng, Yingqing, additional, Zhang, Xin, additional, Xie, Jianhong, additional, Lin, Ling, additional, Soucek, Miroslav, additional, Widimsky, Jiri, additional, Cifkova, Renata, additional, Vaclavik, Jan, additional, Ullrych, Martin, additional, Lukac, Martin, additional, Rychlik, Ivan, additional, Guldager Lauridsen, Thomas, additional, Kantola, Ilkka, additional, Taurio, Jyrki, additional, Ukkola, Olavi, additional, Ormezzano, Olivier, additional, Gosse, Philippe, additional, Azizi, Michel, additional, Courand, Pierre-Yves, additional, Delsart, Pascal, additional, Tartiere, Jean Michel, additional, Mahfoud, Felix, additional, Schmieder, Roland, additional, Stegbauer, Johannes, additional, Lurz, Philipp, additional, Koziolek, Michael, additional, Ott, Christian, additional, Toursarkissian, Nicole, additional, Tsioufis, Konstantinos, additional, Kyfnidis, Konstantinos, additional, Manolis, Athanasios, additional, Patsilinakos, Sotirios, additional, Zebekakis, Pantelis, additional, Karavidas, Apostolos, additional, Denes, Pall, additional, Bezzegh, Katalin, additional, Zsom, Marianna, additional, Kovacs, Laszlo, additional, Sharabi, Yehonatan, additional, Elias, Mazen, additional, Sukholutsky, Ivetta, additional, Yosefy, Chaim, additional, Kenis, Irina, additional, Atar, Shaul, additional, Volpe, Massimo, additional, Maria Lorenza, Muiesan, additional, Taddei, Stefano, additional, Grassi, Guido, additional, Veglio, Franco, additional, Son, Jung Woo, additional, Kim, Jang-Young, additional, Park, Joong-Il, additional, Lee, Chang Hoon, additional, Lee, Hae-Young, additional, Raugaliene, Rasa, additional, Marcinkeviciene, Jolanta Elena, additional, Kavaliauskiene, Roma, additional, Deinum, Jaap, additional, Kroon, Abraham, additional, van den Born, Bert-Jan, additional, Januszewicz, Andrzej, additional, Tykarski, Andrzej, additional, Walczewska, Jolanta, additional, Gaciong, Zbigniew, additional, Wiecek, Andrzej, additional, Chrostowska, Marzena, additional, Kleinrok, Andrzej, additional, Krekora, Jan, additional, Kania, Grzegorz, additional, Podrazka-Szczepaniak, Anna, additional, Golawski, Cezary, additional, Podziewski, Maciej, additional, Kaczmarek, Barbara, additional, Skoczylas, Grzegorz, additional, Wilkolaski, Andrzej, additional, Wozniak, Iwona, additional, Janik-Palazzolo, Marzena, additional, Rewerska, Barbara, additional, Konradi, Aleksandra, additional, Shvarts, Yuriy, additional, Pecherina, Tamara, additional, Nikolaev, Konstantin, additional, Liudmila, Gapon, additional, Orlikova, Olga, additional, Mordovin, Viktor, additional, Petrochenkova, Natalia, additional, Kamalov, Gadel, additional, Kosmacheva, Elena, additional, Tyrenko, Vadim, additional, Gorbunov, Vladimir, additional, Obrezan, Andrey, additional, Supryadkina, Tatiana, additional, Ler, Irina, additional, Kotenko, Oleg, additional, Kuzin, Anatoly, additional, Martínez García, Fernando, additional, Redon, Josep, additional, Oliveras, Anna, additional, Beltran Romero, Luis, additional, Shatylo, Valerii, additional, Rudenko, Leonid, additional, Bazylevych, Andriy, additional, Rudyk, Yurii, additional, Karpenko, Oleksandr, additional, Stanislavchuk, Mykola, additional, Tseluyko, Vira, additional, Kushnir, Mykola, additional, Asanov, Ervin, additional, Sirenko, Yuriy, additional, Yagensky, Andriy, additional, Collier, David, additional, Gupta, Pankaj, additional, Webb, David, additional, MacLeod, Mary, additional, McLay, James, additional, Peace, Aaron, additional, Arora, Samir, additional, Buchanan, Patricia, additional, Harris, Robert, additional, Degarmo, Ronald, additional, Guillen, Mario, additional, Karns, Adam, additional, Neutel, Joel, additional, Paliwal, Yogesh, additional, Pettis, Karlton, additional, Toth, Phillip D., additional, Wayne, Jeffrey M., additional, Butcher, Michael Bain, additional, Diller, Phillip M., additional, Oparil, Suzanne, additional, Calhoun, David, additional, Brautigam, Donald, additional, Flack, John, additional, Goldman, Jesse M., additional, Rashidi, Arash, additional, Aslam, Nabeel, additional, Haley, William, additional, Andrawis, Nabil, additional, Lang, Brian, additional, Miller, Randy, additional, Powell, James, additional, Dewhurst, Robert, additional, Pritchard, James, additional, Khanna, Dinesh, additional, Tang, Dennis, additional, Gabra, Nashwa, additional, Park, Jean, additional, Jones, Conigliaro, additional, Scott, Cranford, additional, Luna, Blanca, additional, Mussaji, Murtaza, additional, Bhagwat, Ravi, additional, Bauer, Michael, additional, McGinty, John, additional, Nambiar, Rajesh, additional, Sangrigoli, Renee, additional, Davis, William Ross, additional, Eaves, William, additional, McGrew, Frank, additional, Awad, Ahmed, additional, Bolster, Eric, additional, Scott, David, additional, Kalirao, Paramjit, additional, Dabel, Pascal, additional, Calhoun, Wesley, additional, Gouge, Steven, additional, Warren, Mark, additional, Lawrence, Mary Katherine, additional, Jamal, Aamir, additional, El-Shahawy, Mohamed, additional, Mercado, Carlos, additional, Kumar, Jayant, additional, Velasquez-Mieyer, Pedro, additional, Busch, Robert, additional, Lewis, Todd, additional, and Rich, Lisa, additional

Published
2022
Full Text
View/download PDF

208. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial

Author

Azizi, Michel, Saxena, Manish, Wang, Yale, Jenkins, J. Stephen, Devireddy, Chandan, Rader, Florian, Fisher, Naomi D.L., Schmieder, Roland E., Mahfoud, Felix, Lindsey, Jason, Sanghvi, Kintur, Todoran, Thomas M., Pacella, John, Flack, John, Daemen, Joost, Sharp, Andrew S.P., Lurz, Philipp, Bloch, Michael J., Weber, Michael A., Lobo, Melvin D., Basile, Jan, Claude, Lisa, Reeve-Stoffer, Helen, McClure, Candace K., Kirtane, Ajay J., and Cardiology

Abstract

IMPORTANCE: Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and hypertension that is resistant to treatment. OBJECTIVE: To study the efficacy and safety of ultrasound renal denervation without the confounding influence of antihypertensive medications in patients with hypertension. DESIGN, SETTING, AND PARTICIPANTS: Sham-controlled, randomized clinical trial with patients and outcome assessors blinded to treatment assignment that was conducted between January 14, 2019, and March 25, 2022, at 37 centers in the US and 24 centers in Europe, with randomization stratified by center. Patients aged 18 years to 75 years with hypertension (seated office systolic BP [SBP] ≥140 mm Hg and diastolic BP [DBP] ≥90 mm Hg despite taking up to 2 antihypertensive medications) were eligible if they had an ambulatory SBP/DBP of 135/85 mm Hg or greater and an SBP/DBP less than 170/105 mm Hg after a 4-week washout of their medications. Patients with an estimated glomerular filtration rate of 40 mL/min/1.73 m2 or greater and with suitable renal artery anatomy were randomized 2:1 to undergo ultrasound renal denervation or a sham procedure. Patients were to abstain from antihypertensive medications until the 2-month follow-up unless prespecified BP criteria were exceeded and were associated with clinical symptoms. INTERVENTIONS: Ultrasound renal denervation vs a sham procedure. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the mean change in daytime ambulatory SBP at 2 months. The primary safety composite outcome of major adverse events included death, kidney failure, and major embolic, vascular, cardiovascular, cerebrovascular, and hypertensive events at 30 days and renal artery stenosis greater than 70% detected at 6 months. The secondary outcomes included mean change in 24-hour ambulatory SBP, home SBP, office SBP, and all DBP parameters at 2 months. RESULTS: Among 1038 eligible patients, 150 were randomized to ultrasound renal denervation and 74 to a sham procedure (mean age, 55 years [SD, 9.3 years]; 28.6% female; and 16.1% self-identified as Black or African American). The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, -7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, -1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, -6.3 mm Hg [95% CI, -9.3 to -3.2 mm Hg], P

Published
2023

212. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial

Author

Scheller, Bruno, Rissanen, Tuomas T., Farah, Ahmed, Ohlow, Marc-Alexander, Mangner, Norman, Wöhrle, Jochen, Möbius-Winkler, Sven, Weilenmann, Daniel, Leibundgut, Gregor, Cuculi, Florim, Gilgen, Nicole, Coslovsky, Michael, Mahfoud, Felix, and Jeger, Raban V.

Subjects
coronary vessels, percutaneous coronary intervention, drug-eluting stents, population, mortality
Published
2022
Full Text
View/download PDF

213. Sex differences in arterial hypertension A scientific statement from the ESC Council on Hypertension, the European Association of Preventive Cardiology, Association of Cardiovascular Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the ESC Working Group on Cardiovascular Pharmacotherapy

Author

Gerdts, Eva, Sudano, Isabella, Brouwers, Sofie, Borghi, Claudio, Bruno, Rosa Maria, Ceconi, Claudio, Cornelissen, Veronique, Diévart, François, Ferrini, Marc, Kahan, Thomas, Løchen, Maja Lisa, Maas, Angela H E M, Mahfoud, Felix, Mihailidou, Anastasia S, Moholdt, Trine, Parati, Gianfranco, de Simone, Giovanni, Faculty of Medicine and Pharmacy, Brussels Heritage Lab, Pharmaceutical and Pharmacological Sciences, and Experimental Pharmacology

Subjects
hypertension, Cardiac & Cardiovascular Systems, CONSENSUS DOCUMENT, BLOOD-PRESSURE, END-POINT REDUCTION, Hypertension-mediated organ damage, ANTIHYPERTENSIVE TREATMENT, LOSARTAN INTERVENTION, sex hormones, pharmacological treatment, LEFT-VENTRICULAR HYPERTROPHY, Internal Medicine, Blood Pressure regulators, Sex hormones, GENDER-DIFFERENCES, Science & Technology, LEFT ATRIAL SIZE, Cardiovascular disease, adverse events, PULSE-WAVE VELOCITY, Adverse events, Hypertension, Cardiovascular System & Cardiology, RISK-FACTORS, Sex, pharmacology, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, Pharmacological treatment
Abstract

There is strong evidence that sex chromosomes and sex hormones influence blood pressure (BP) regulation, distribution of cardiovascular (CV) risk factors and co-morbidities differentially in females and males with essential arterial hypertension. The risk for CV disease increases at a lower BP level in females than in males, suggesting that sex-specific thresholds for diagnosis of hypertension may be reasonable. However, due to paucity of data, in particularly from specifically designed clinical trials, it is not yet known whether hypertension should be differently managed in females and males, including treatment goals and choice and dosages of antihypertensive drugs. Accordingly, this consensus document was conceived to provide a comprehensive overview of current knowledge on sex differences in essential hypertension including BP development over the life course, development of hypertension, pathophysiologic mechanisms regulating BP, interaction of BP with CV risk factors and co-morbidities, hypertension-mediated organ damage in the heart and the arteries, impact on incident CV disease, and differences in the effect of antihypertensive treatment. The consensus document also highlights areas where focused research is needed to advance sex-specific prevention and management of hypertension. ispartof: EUROPEAN HEART JOURNAL vol:43 issue:46 pages:4777-4788 ispartof: location:England status: published

Published
2022

214. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation

Author

Azizi, Michel, Mahfoud, Felix, Weber, Michael, Sharp, Andrew, Schmieder, Roland, Lurz, Philipp, Lobo, Melvin, Fisher, Naomi, Daemen, Joost, Bloch, Michael, Basile, Jan, Sanghvi, Kintur, Saxena, Manish, Gosse, Philippe, Jenkins, J. Stephen, Levy, Terry, Persu, Alexandre, Kably, Benjamin, Claude, Lisa, Reeve-Stoffer, Helen, Mcclure, Candace, Kirtane, Ajay, Mullin, Christopher, Thackeray, Lisa, Chertow, Glenn, Kahan, Thomas, Dauerman, Harold, Ullery, Steven, Abbott, J. Dawn, Loening, Andreas, Zagoria, Ron, Costello, John, Krathan, Courtney, Lewis, Luot, Mcelvarr, Andrew, Reilly, John, Cash, Michael, Williams, Shannon, Jarvis, Maria, Fong, Pete, Laffer, Cheryl, Gainer, James, Robbins, Mark, Crook, Sherron, Maddel, Sarita, Hsi, David, Martin, Scott, Portnay, Edward, Ducey, Maryanne, Rose, Suzanne, Delmastro, Elizabeth, Bangalore, Sripal, Williams, Stephen, Cabos, Stanley, Rodriguez Alvarez, Carolina, Todoran, Thomas, Powers, Eric, Hodskins, Emily, Paladugu, Vijay, Tecklenburg, Anna, Devireddy, Chandan, Lea, Janice, Wells, Bryan, Fiebach, Amanda, Merlin, Claudia, Rader, Florian, Dohad, Suhail, Kim, Hyun-Min, Rashid, Mohammad, Abraham, Josephine, Owan, Theophilus, Abraham, Anu, Lavasani, Iran, Neilson, Hailey, Calhoun, David, Mcelderry, Thomas, Maddox, William, Oparil, Suzanne, Kinder, Sheila, Radhakrishnan, Jai, Batres, Candido, Edwards, Suzanne, Garasic, Joseph, Drachman, Doug, Zusman, Randy, Rosenfield, Kenneth, Do, Danny, Khuddus, Matheen, Zentko, Suzanne, O'Meara, James, Barb, Ilie, Foster, Abby, Boyette, Alice, Wang, Yale, Jay, Desmond, Skeik, Nedaa, Schwartz, Robert, Peterson, Rose, Goldman, Jo Anne, Goldman, Jessie, Ledley, Gary, Katof, Nancy, Potluri, Srinivasa, Biedermann, Scott, Ward, Jacquelyn, White, Megan, Mauri, Laura, Sobieszczky, Piotr, Smith, Alex, Aseltine, Laura, Stouffer, Rick, Hinderliter, Alan, Pauley, Eric, Wade, Tyrone, Zidar, David, Shishehbor, Mehdi, Effron, Barry, Costa, Marco, Semenec, Terence, Roongsritong, Chanwit, Nelson, Priscilla, Neumann, Bridget, Cohen, Debbie, Giri, Jay, Neubauer, Robin, Vo, Thu, Chugh, Atul, Huang, Pei-Hsiu, Jose, Powell, Flack, John, Fishman, Robert, Jones, Michael, Adams, Todd, Bajzer, Christopher, Mathur, Anthony, Jain, Ajay, Balawon, Armida, Zongo, Olivier, Bent, Clare, Beckett, David, Lakeman, Nicki, Kennard, Sarah, D’souza, Richard, Statton, Sarah, Wilkes, Lindsay, Anning, Christine, Sayer, Jeremy, Iyer, Sudha Ganesh, Robinson, Nicholas, Sevillano, Annaliza, Ocampo, Madelaine, Gerber, Robert, Faris, Mohamad, Marshall, Andrew John, Sinclair, Janet, Pepper, Hayley, Davies, Justin, Chapman, Neil, Burak, Paula, Carvelli, Paula, Jadhav, Sachin, Quinn, Jane, Rump, Lars Christian, Stegbauer, Johannes, Schimmöller, Lars, Potthoff, Sebastian, Schmid, Claudia, Roeder, Sylvia, Weil, Joachim, Hafer, Lukas, Agdirlioglu, Tolga, Köllner, Tanja, Böhm, Michael, Ewen, Sebastian, Kulenthiran, Saarraaken, Wachter, Angelika, Koch, Christina, Fengler, Karl, Rommel, Karl-Philipp, Trautmann, Kai, Petzold, Martin, Ott, Christian, Schmid, Axel, Uder, Michael, Heinritz, Ulrike, Fröhlich-Endres, Kerstin, Genth-Zotz, Sabine, Kämpfner, Denise, Grawe, Armin, Höhne, Johannes, Kaesberger, Bärbel, von Zur Mühlen, Constantin, Wolf, Dennis, Welzel, Markus, Heinrichs, Gudrun, Trabitzsch, Barbara, Cremer, Antoine, Trillaud, Hervé, Papadopoulos, Panteleimon, Maire, Florent, Gaudissard, Julie, Sapoval, Marc, Livrozet, Marine, Lorthioir, Aurélien, Amar, Laurence, Paquet, Valérie, Pathak, Atul, Honton, Benjamin, Cottin, Marianne, Petit, Frédéric, Lantelme, Pierre, Berge, Constance, Courand, Pierre-Yves, Langevin, Fatou, Delsart, Pascal, Longere, Benjamin, Ledieu, Guillaume, Pontana, François, Sommeville, Coralie, Bertrand, Fabien, Feyz, Lida, Zeijen, Victor, Ruiter, Arno, Huysken, Elisabeth, Blankestijn, Peter, Voskuil, Michiel, Rittersma, Zwaantina, Dolmans, Helma, Kroon, A.A., van Zwam, W.H., Vranken, Jeannique, de Haan., Claudia, Renkin, Jean, Maes, Frédéric, Beauloye, Christophe, Lengelé, Jean-Philippe, Huyberechts, Dominique, Bouvie, Anne, Witkowski, Adam, Januszewicz, Andrzej, Kądziela, Jacek, Prejbisj, Aleksander, Hering, Dagmara, Ciecwierz, Dariusz, Jaguszewski, Milosz, Owczuk, Radoslaw, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris] (DMU CARTE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Saarland University [Saarbrücken], Biotechnologie et signalisation cellulaire (BSC), Université de Strasbourg (UNISTRA)-Institut de recherche de l'Ecole de biotechnologie de Strasbourg (IREBS)-Centre National de la Recherche Scientifique (CNRS), University Hospital of Wales (UHW), University of Exeter, Universitätsklinikum Erlangen [Erlangen], Leipzig University, Queen Mary University of London (QMUL), Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), Erasmus University Medical Center [Rotterdam] (Erasmus MC), University of Nevada [Reno], Medical University of South Carolina [Charleston] (MUSC), Hôpital Saint-André, Royal Bournemouth Hospital, Université Catholique de Louvain = Catholic University of Louvain (UCL), Cliniques Universitaires Saint-Luc [Bruxelles], Plant Health Institute of Montpellier (UMR PHIM), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Montpellier, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Université de Montpellier (UM), Columbia University Medical Center (CUMC), Columbia University [New York], Danderyds sjukhus = Danderyd University Hospital, University of Vermont [Burlington], Stanford University, Argolyn Bioscience, Inc., and Argolyn Bioscience

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Auteurs : RADIANCE-HTN Investigators; International audience; Importance Although early trials of endovascular renal denervation (RDN) for patients with resistant hypertension (RHTN) reported inconsistent results, ultrasound RDN (uRDN) was found to decrease blood pressure (BP) vs sham at 2 months in patients with RHTN taking stable background medications in the Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN TRIO) trial. Objectives To report the prespecified analysis of the persistence of the BP effects and safety of uRDN vs sham at 6 months in conjunction with escalating antihypertensive medications. Design, Setting, and Participants This randomized, sham-controlled, clinical trial with outcome assessors and patients blinded to treatment assignment, enrolled patients from March 11, 2016, to March 13, 2020. This was an international, multicenter study conducted in the US and Europe. Participants with daytime ambulatory BP of 135/85 mm Hg or higher after 4 weeks of single-pill triple-combination treatment (angiotensin-receptor blocker, calcium channel blocker, and thiazide diuretic) with estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73 m 2 or greater were randomly assigned to uRDN or sham with medications unchanged through 2 months. From 2 to 5 months, if monthly home BP was 135/85 mm Hg or higher, standardized stepped-care antihypertensive treatment starting with aldosterone antagonists was initiated under blinding to treatment assignment. Interventions uRDN vs sham procedure in conjunction with added medications to target BP control. Main Outcomes and Measures Six-month change in medications, change in daytime ambulatory systolic BP, change in home systolic BP adjusted for baseline BP and medications, and safety. Results A total of 65 of 69 participants in the uRDN group and 64 of 67 participants in the sham group (mean [SD] age, 52.4 [8.3] years; 104 male [80.6%]) with a mean (SD) eGFR of 81.5 (22.8) mL/min/1.73 m 2 had 6-month daytime ambulatory BP measurements. Fewer medications were added in the uRDN group (mean [SD], 0.7 [1.0] medications) vs sham (mean [SD], 1.1 [1.1] medications; P = .045) and fewer patients in the uRDN group received aldosterone antagonists at 6 months (26 of 65 [40.0%] vs 39 of 64 [60.9%]; P = .02). Despite less intensive standardized stepped-care antihypertensive treatment, mean (SD) daytime ambulatory BP at 6 months was 138.3 (15.1) mm Hg with uRDN vs 139.0 (14.3) mm Hg with sham (additional decreases of −2.4 [16.6] vs −7.0 [16.7] mm Hg from month 2, respectively), whereas home SBP was lowered to a greater extent with uRDN by 4.3 mm Hg (95% CI, 0.5-8.1 mm Hg; P = .03) in a mixed model adjusting for baseline and number of medications. Adverse events were infrequent and similar between groups. Conclusions and Relevance In this study, in patients with RHTN initially randomly assigned to uRDN or a sham procedure and who had persistent elevation of BP at 2 months after the procedure, standardized stepped-care antihypertensive treatment escalation resulted in similar BP reduction in both groups at 6 months, with fewer additional medications required in the uRDN group. Trial Registration ClinicalTrials.gov Identifier: NCT02649426

Published
2022

219. Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial

Author

Stoiber, Lukas, Mahfoud, Felix, Zamani, Seyedeh Mahsa, Lapinskas, Tomas, Böhm, Michael, Ewen, Sebastian, Kulenthiran, Saarraaken, Schlaich, Markus P, Esler, Murray D, Hammer, Tommy, Stensæth, Knut Haakon, Pieske, Burkert, Dreysse, Stephan, Fleck, Eckart, Kühne, Titus, Kelm, Marcus, Stawowy, Philipp, and Kelle, Sebastian

Subjects
Resistant hypertension, Aortic distensibility, Renal denervation, Cardiovascular magnetic resonance, CMR, Vascular stiffness, Compliance
Published
2022
Full Text
View/download PDF

220. Hypertension management in patients with cardiovascular comorbidities

Author

Lauder, Lucas, primary, Mahfoud, Felix, additional, Azizi, Michel, additional, Bhatt, Deepak L, additional, Ewen, Sebastian, additional, Kario, Kazuomi, additional, Parati, Gianfranco, additional, Rossignol, Patrick, additional, Schlaich, Markus P, additional, Teo, Koon K, additional, Townsend, Raymond R, additional, Tsioufis, Costas, additional, Weber, Michael A, additional, Weber, Thomas, additional, and Böhm, Michael, additional

Published
2022
Full Text
View/download PDF

223. Glycyrrhizin through liquorice intake modulates ACE2 and HMGB1 levels—A pilot study in healthy individuals with implications for COVID-19 and ARDS

Author

Buder, Felix, primary, Selejan, Simina-Ramona, additional, Hohl, Mathias, additional, Kindermann, Michael, additional, Herr, Christian, additional, Lepper, Philipp M., additional, Bals, Robert, additional, Salzberger, Bernd, additional, Mahfoud, Felix, additional, and Böhm, Michael, additional

Published
2022
Full Text
View/download PDF

224. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial

Author

Kario, Kazuomi, primary, Mahfoud, Felix, additional, Kandzari, David E., additional, Townsend, Raymond R., additional, Weber, Michael A., additional, Schmieder, Roland E., additional, Tsioufis, Konstantinos, additional, Pocock, Stuart, additional, Brar, Sandeep, additional, Hettrick, Douglas A., additional, Fahy, Martin, additional, and Böhm, Michael, additional

Published
2022
Full Text
View/download PDF

225. Model-Based Analysis of SARS-CoV-2 Infections, Hospitalization and Outcome in Germany, the Federal States and Districts

Author

Dings, Christiane, primary, Götz, Katharina Martha, additional, Och, Katharina, additional, Sihinevich, Iryna, additional, Werthner, Quirin, additional, Smola, Sigrun, additional, Bliem, Marc, additional, Mahfoud, Felix, additional, Volk, Thomas, additional, Kreuer, Sascha, additional, Rissland, Jürgen, additional, Selzer, Dominik, additional, and Lehr, Thorsten, additional

Published
2022
Full Text
View/download PDF

226. Sex differences in arterial hypertension

Author

Gerdts, Eva, primary, Sudano, Isabella, additional, Brouwers, Sofie, additional, Borghi, Claudio, additional, Bruno, Rosa Maria, additional, Ceconi, Claudio, additional, Cornelissen, Véronique, additional, Diévart, François, additional, Ferrini, Marc, additional, Kahan, Thomas, additional, Løchen, Maja-Lisa, additional, Maas, Angela H E M, additional, Mahfoud, Felix, additional, Mihailidou, Anastasia S, additional, Moholdt, Trine, additional, Parati, Gianfranco, additional, and de Simone, Giovanni, additional

Published
2022
Full Text
View/download PDF

228. Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry

Author

Schmieder, Roland E, primary, Mahfoud, Felix, additional, Mancia, Giuseppe, additional, Narkiewicz, Krzysztof, additional, Ruilope, Luis, additional, Hutton, David W, additional, Cao, Khoa N, additional, Hettrick, Douglas A, additional, Fahy, Martin, additional, Schlaich, Markus P, additional, Böhm, Michael, additional, and Pietzsch, Jan B, additional

Published
2022
Full Text
View/download PDF

229. Combined Analysis of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions

Author

Scheller, Bruno, primary, Mangner, Norman, additional, Abdul Kader, Muhamad Ali S.K., additional, Wan Ahmad, Wan Azman, additional, Jeger, Raban, additional, Wöhrle, Jochen, additional, Ong, Tiong Kiam, additional, Liew, Houng Bang, additional, Gori, Tommaso, additional, Mahfoud, Felix, additional, Nuruddin, Amin Ariff, additional, Woitek, Felix, additional, Abidin, Imran Zainal, additional, Schwenke, Carsten, additional, Schnorr, Beatrix, additional, Mohd Ali, Rosli, additional, Scheller, Bruno, additional, Rastoul, Bianca, additional, Hollinger, Nicole, additional, Ewen, Sebastian, additional, Böhm, Michael, additional, Vukadinovic, Davor, additional, Kulenthiran, Saaraken, additional, Schwarz, Viktoria, additional, Clever, Yvonne P., additional, Linke, Axel, additional, Höllriegel, Robert, additional, Winzer, Ephraim, additional, Jellinghaus, Stefanie, additional, Hommel, Jennifer, additional, Abdul Kader, Muhamad Ali bin Sheikh, additional, Ismail, Muhammad Dzafir, additional, Mahmood Zuhdi, Ahmad Syadi, additional, Syed Mansor, Syed Mukhtar, additional, Kaiser, Christoph, additional, Fahrni, Gregor, additional, Gilgen, Nicole, additional, Harder-Allgöwer, Andrea, additional, Baumgartner, Margarete, additional, Sinisa, Markovic, additional, Smirnova, Olga, additional, Kiam Ong, Tiong, additional, Yip Fong, Alan Yean, additional, Khiew, Ning Zan, additional, Said, Asri Bin, additional, Cham, Yee Ling, additional, Oon, Yen Yee, additional, Koh, Keng Tat, additional, Voon, Chi Yen, additional, Mohd Amin, Nor Hanim bt, additional, Johan, Wilson anak, additional, Fui Jien, Mabelle Wong, additional, Shu Theng, Melanie Chong, additional, Gori, Tomasso, additional, Omar, Al Fazir, additional, Azmi, Shaiful, additional, Kandasamy, Balachandran, additional, Mohamed Yusoff, Ahmad Khairuddin, additional, Selamat, Salizah, additional, Kutschera, Maren, additional, and Mathana Sundram, Thavin Kumar, additional

Published
2022
Full Text
View/download PDF

240. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension

Author

Williams, Bryan, Mancia, Giuseppe, Spiering, Wilko, Agabiti Rosei, Enrico, Azizi, Michel, Burnier, Michel, Clement, Denis L., Coca, Antonio, de Simone, Giovanni, Dominiczak, Anna, Kahan, Thomas, Mahfoud, Felix, Redon, Josep, Ruilope, Luis, Zanchetti, Alberto, Kerins, Mary, Kjeldsen, Sverre E., Kreutz, Reinhold, Laurent, Stephane, Lip, Gregory Y.H., McManus, Richard, Narkiewicz, Krzysztof, Ruschitzka, Frank, Schmieder, Roland E., Shlyakhto, Evgeny, Tsioufis, Costas, Aboyans, Victor, and Desormais, Ileana

Published
2018
Full Text
View/download PDF

243. Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR‐Preserved trial.

Author

Böhm, Michael, Butler, Javed, Krawczyk, Marcin, Mahfoud, Felix, Haring, Bernhard, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Brueckmann, Martina, Ofstad, Anne Pernille, Schüler, Elke, Wanner, Christoph, Verma, Subodh, Packer, Milton, and Anker, Stefan D.

Subjects
BRAIN natriuretic factor, HEART failure patients, VENTRICULAR ejection fraction, EMPAGLIFLOZIN, LIVER
Abstract

Aim: The prognostic implication of elevated liver tests in heart failure with preserved ejection fraction (HFpEF) is uncertain. This analysis investigates the association of liver markers with hospitalization for heart failure (HHF) and cardiovascular death (CVD), and the treatment effect of empagliflozin across the range of liver marker levels. Methods and results: The double‐blind, placebo‐controlled EMPEROR‐Preserved (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure with Preserved Ejection Fraction) enrolled 5988 patients with HFpEF (ejection fraction >40%). Patients in New York Heart Association class II–IV and elevated N‐terminal pro‐B‐type natriuretic peptide were randomized to receive empagliflozin 10 mg daily or placebo in addition to usual therapy. Patients with significant liver disease were excluded. The primary endpoint was time to first adjudicated HHF or CVD. We explored the association of liver function abnormalities with heart failure outcomes in patients on placebo, the effects of empagliflozin on liver tests and the treatment effects of empagliflozin on heart failure outcomes across categories of liver laboratory values. High alkaline phosphatase (p trend < 0.0001), low albumin (p trend < 0.0001) and high bilirubin (p = 0.02) were associated with poorer outcomes for HHF or CVD, while high aspartate aminotransferase was not, and high alanine aminotransferase was associated with better outcomes. Empagliflozin had no significant effects on liver tests compared to placebo except for albumin which was significantly increased. The treatment effect of empagliflozin on outcomes was not modified by liver tests. Conclusion: Abnormalities of liver function tests are associated differently with heart failure outcomes. Salutary effects of empagliflozin on liver tests were not observed although albumin increased. The treatment benefits of empagliflozin were not affected by baseline values of liver parameters. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

244. Hypertension management in patients with cardiovascular comorbidities.

Author

Lauder, Lucas, Mahfoud, Felix, Azizi, Michel, Bhatt, Deepak L, Ewen, Sebastian, Kario, Kazuomi, Parati, Gianfranco, Rossignol, Patrick, Schlaich, Markus P, Teo, Koon K, Townsend, Raymond R, Tsioufis, Costas, Weber, Michael A, Weber, Thomas, and Böhm, Michael

Subjects
GLUCAGON-like peptide-1 receptor, SODIUM-glucose cotransporter 2 inhibitors, HYPERTENSION, BLOOD pressure, CALCIUM antagonists
Abstract

Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence of obesity, and socioeconomic and environmental changes, its incidence increases worldwide. Hypertension commonly coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading to risk amplification. Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin–angiotensin system blockers, calcium channel blockers, and/or a diuretic. Comorbidities often complicate management. New drugs such as angiotensin receptor-neprilysin inhibitors, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists improve CV and renal outcomes. Catheter-based renal denervation could offer an alternative treatment option in comorbid hypertension associated with increased sympathetic nerve activity. This review summarises the latest clinical evidence for managing hypertension with CV comorbidities. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

245. International Expert Consensus Statement: Percutaneous Transluminal Renal Denervation for the Treatment of Resistant Hypertension

Author

Schlaich, Markus P., Schmieder, Roland E., Bakris, George, Blankestijn, Peter J., Böhm, Michael, Campese, Vito M., Francis, Darrel P., Grassi, Guido, Hering, Dagmara, Katholi, Richard, Kjeldsen, Sverre, Krum, Henry, Mahfoud, Felix, Mancia, Giuseppe, Messerli, Franz H., Narkiewicz, Krzysztof, Parati, Gianfranco, Rocha-Singh, Krishna J., Ruilope, Luis M., Rump, Lars C., Sica, Domenic A., Sobotka, Paul A., Tsioufis, Costas, Vonend, Oliver, Weber, Michael A., Williams, Bryan, Zeller, Thomas, and Esler, Murray D.

Published
2013
Full Text
View/download PDF

248. Renal denervation in hypertensive patients not on blood pressure lowering drugs

Author

De Jager, Rosa L., Sanders, Margreet F., Bots, Michiel L., Lobo, Melvin D., Ewen, Sebastian, Beeftink, Martine M. A., Böhm, Michael, Daemen, Joost, Dörr, Oliver, Hering, Dagmara, Mahfoud, Felix, Nef, Holger, Ott, Christian, Saxena, Manish, Schmieder, Roland E., Schlaich, Markus P., Spiering, Wilko, Tonino, Pim. A. L., Verloop, Willemien L., Vink, Eva E., Vonken, Evert-Jan, Voskuil, Michiel, Worthley, Stephen G., and Blankestijn, Peter J.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results